Immune tolerance induction (ITI) with a FVIII concentrate with high VWF content in inhibitor patients with previous unsuccessful ITI and/or negative predictors of ITI response

被引：0
|
作者：
Coppola, A. [1 ]
Arbasi, M. [2 ]
Biasoli, C. [3 ]
Messina, M. [4 ]
Tagliaferri, A. [5 ]
Scaraggi, F. [6 ]
机构：
[1] Federico II Univ Hosp, Reg Reference Ctr Coagulat Disorders, Milan, Italy
[2] Hosp Piacenza, Ctr Bleeding Disorders, Piacenza, Italy
[3] Bufalini Hosp, Transfus & Haemophilia Ctr, Cesena, Italy
[4] Regina Margherita Children Hosp, Paediat Reg Reference Ctr Bleeding & Thrombot Dis, Turin, Italy
[5] Univ Hosp, Reg Reference Ctr Haemophilia, Parma, Italy
[6] Univ Bari, Dept Internal Med, Haemostasis & Thrombosis Ctr, Bari, Italy
来源：
HAEMOPHILIA | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [31] Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis
    Kenet, G.
    Oladapo, A.
    Epstein, J. D.
    Thompson, C.
    Novack, A.
    Nugent, D. J.
    HAEMOPHILIA, 2017, 23 (05) : e394 - e402
  • [32] Prophylactic treatment and Rituximab subsequent immune tolerance induction therapy to improve inhibitor eradication on resistant ITI in severe hemophilia A patients with inhibitor
    Chen, Yeu-Chin
    Cheng, Shin-Nan
    HAEMOPHILIA, 2016, 22 : 69 - 69
  • [33] IMMUNE TOLERANCE INDUCTION (ITI) IN CHILDREN WITH HAEMOPHILIA A WITH INHIBITOR: IN REGION VIII-BUENOS AIRES- ARGENTINA
    Martinez, M. S.
    Sliba, G.
    Batistelli, S.
    HAEMOPHILIA, 2020, 26 : 105 - 105
  • [34] Factor VIII inhibitor bypass activity (Feiba) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors.
    Kreutz, W
    Escuriola-Ettinghausen, C
    Mentzer, D
    Martinez, I
    Becker, S
    Stoll, H
    Heller, C
    BLOOD, 2000, 96 (11) : 266A - 266A
  • [35] Immune tolerance induction with FVIII/VWF concentrate in an elderly severe haemophilia A patient with high-responding inhibitor
    Tagliaferri, A.
    Rivolta, G.
    Di Perna, C.
    Riccardi, F.
    Ippolito, L.
    Lombardi, M.
    Franchini, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 829 - 830
  • [36] Predictors of the Outcome of Immune Tolerance Induction (ITI) Therapy Among Japanese Pediatric Hemophilia A Patients with F8 Null Mutations
    Yada, Koji
    Nogami, Keiji
    Nakajima, Yuto
    Shima, Midori
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S29 - S30
  • [37] rFIXFc for Immune Tolerance Induction in a Severe Hemophilia B Patient with an Inhibitor and Prior History of ITI Related Nephrotic Syndrome
    Malec, Lynn
    Abshire, Thomas
    Jobe, Shawn
    White, Gilbert
    HAEMOPHILIA, 2018, 24 (04) : E294 - E296
  • [38] IMMUNE TOLERANCE INDUCTION (ITI) WITH A SINGLE FACTOR VIII/VON WILLEBRAND FACTOR CONCENTRATE IN HAEMOPHILIA A PATIENTS WITH INHIBITORS - DATA FROM THE OBSITI STUDY
    Escuriola-Ettingshausen, C.
    HAEMOPHILIA, 2020, 26 : 62 - 63
  • [39] Successful of Immune Tolerance Induction (R-ITI) with Simoctocog Alfa (rhFVIII) in Hemophilia a Patients and High-Titer Inhibitors
    Zanon, Ezio
    Pasca, Samantha
    Marino, Renato
    Molinari, Angelo Claudio
    BLOOD, 2018, 132
  • [40] Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure
    Carcao, M.
    Shapiro, A.
    Hwang, N.
    Pipe, S.
    Ahuja, S.
    Lieuw, K.
    Staber, J.
    Belletrutti, M.
    Sun, H.
    Ding, H.
    Wang, M.
    Price, V.
    Steele, M.
    Tsao, E.
    Feng, J.
    Al-Khateeb, Z.
    Dumont, J.
    Jain, N.
    HAEMOPHILIA, 2019, 25 : 15 - 16
12345